COVID-19 Impact on Anti-Obesity Drugs (Anti-obesity Medication) Market, Global Research Reports 2020-2021

2 Global Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Market Size Analysis

• 2.1 Anti-Obesity Drugs (Anti-obesity Medication) Business Impact Assessment - COVID-19
  • 2.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Anti-Obesity Drugs (Anti-obesity Medication) Market
• 3.5 Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Anti-Obesity Drugs (Anti-obesity Medication) Segments, By Type

• 4.1 Introduction
  • 1.4.1 Prescription Drugs
  • 1.4.2 OTC Drugs
• 4.2 By Type, Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size, 2019-2021
  • 4.2.1 By Type, Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Anti-Obesity Drugs (Anti-obesity Medication) Price, 2020-2021

5 Impact of Covid-19 on Anti-Obesity Drugs (Anti-obesity Medication) Segments, By Application

• 5.1 Overview
  • 5.5.1 Childhood (0-6)
  • 5.5.2 Juvenile (7-17)
  • 5.5.3 Youth (18-40)
  • 5.5.4 Middle Aged (41-60)
  • 5.5.5 Elderly (Above 60)
• 5.2 By Application, Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size, 2019-2021
  • 5.2.1 By Application, Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Anti-Obesity Drugs (Anti-obesity Medication) Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Zafgan
  • 7.1.1 Zafgan Business Overview
  • 7.1.2 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.1.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.1.4 Zafgan Response to COVID-19 and Related Developments
• 7.2 Vivus
  • 7.2.1 Vivus Business Overview
  • 7.2.2 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.2.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.2.4 Vivus Response to COVID-19 and Related Developments
• 7.3 Shionogi
  • 7.3.1 Shionogi Business Overview
  • 7.3.2 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.3.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.3.4 Shionogi Response to COVID-19 and Related Developments
• 7.4 Sanofi
  • 7.4.1 Sanofi Business Overview
  • 7.4.2 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.4.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.4.4 Sanofi Response to COVID-19 and Related Developments
• 7.5 Rhythm Pharmaceuticals
  • 7.5.1 Rhythm Pharmaceuticals Business Overview
  • 7.5.2 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.5.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.5.4 Rhythm Pharmaceuticals Response to COVID-19 and Related Developments
• 7.6 Pfizer
  • 7.6.1 Pfizer Business Overview
  • 7.6.2 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.6.4 Pfizer Response to COVID-19 and Related Developments
• 7.7 Orexigen Therapeutics
  • 7.7.1 Orexigen Therapeutics Business Overview
  • 7.7.2 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.7.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.7.4 Orexigen Therapeutics Response to COVID-19 and Related Developments
• 7.8 Novo Nordisk
  • 7.8.1 Novo Nordisk Business Overview
  • 7.8.2 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.8.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.8.4 Novo Nordisk Response to COVID-19 and Related Developments
• 7.9 Norgine
  • 7.9.1 Norgine Business Overview
  • 7.9.2 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.9.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.9.4 Norgine Response to COVID-19 and Related Developments
• 7.10 Nalpropion Pharmaceuticals Inc.
  • 7.10.1 Nalpropion Pharmaceuticals Inc. Business Overview
  • 7.10.2 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.10.3 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.10.4 Nalpropion Pharmaceuticals Inc. Response to COVID-19 and Related Developments
• 7.11 Merck
  • 7.11.1 Merck Business Overview
  • 7.11.2 Merck Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.11.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.11.4 Merck Response to COVID-19 and Related Developments
• 7.12 GlaxoSmithKline
  • 7.12.1 GlaxoSmithKline Business Overview
  • 7.12.2 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.12.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.12.4 GlaxoSmithKline Response to COVID-19 and Related Developments
• 7.13 F.Hoffmann-La Roche
  • 7.13.1 F.Hoffmann-La Roche Business Overview
  • 7.13.2 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.13.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.13.4 F.Hoffmann-La Roche Response to COVID-19 and Related Developments
• 7.14 Eisai
  • 7.14.1 Eisai Business Overview
  • 7.14.2 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.14.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.14.4 Eisai Response to COVID-19 and Related Developments
• 7.15 Boehringer Ingelheim
  • 7.15.1 Boehringer Ingelheim Business Overview
  • 7.15.2 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.15.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.15.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
• 7.16 Bayer AG
  • 7.16.1 Bayer AG Business Overview
  • 7.16.2 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.16.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.16.4 Bayer AG Response to COVID-19 and Related Developments
• 7.17 AstraZeneca
  • 7.17.1 AstraZeneca Business Overview
  • 7.17.2 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.17.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.17.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.18 Arena Pharmaceuticals
  • 7.18.1 Arena Pharmaceuticals Business Overview
  • 7.18.2 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.18.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.18.4 Arena Pharmaceuticals Response to COVID-19 and Related Developments
• 7.19 Amylin
  • 7.19.1 Amylin Business Overview
  • 7.19.2 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.19.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.19.4 Amylin Response to COVID-19 and Related Developments
• 7.20 Alizyme
  • 7.20.1 Alizyme Business Overview
  • 7.20.2 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Quarterly Production and Revenue, 2020
  • 7.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
  • 7.20.4 Alizyme Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Anti-Obesity Drugs (Anti-obesity Medication) Supply Chain Analysis
  • 8.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Anti-Obesity Drugs (Anti-obesity Medication) Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Anti-Obesity Drugs (Anti-obesity Medication) Distribution Channels
  • 8.2.2 Covid-19 Impact on Anti-Obesity Drugs (Anti-obesity Medication) Distribution Channels
  • 8.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
• 8.3 Anti-Obesity Drugs (Anti-obesity Medication) Customers

9 Key Findings

10 Appendix

• 10.1 About Us